Repare Therapeutics returned to profitability in Q3 2025 with $3.3 million in net income, driven by a $11.6 million licensing revenue from Debiopharm. Operating expenses fell significantly due to prior restructuring efforts and the out-licensing of the lunresertib program. The company also recognized a gain from the termination of a collaboration agreement. Cash and equivalents stood at $72.8 million at quarter end.

Revenue was $250,000 from collaboration agreements; operating loss was $17.8M and net loss was $16.7M (EPS -$0.39). Cash and cash equivalents were $67.7M, with $109.5M including marketable securities.

Repare Therapeutics Inc. experienced a net loss of $30.043 million in the first quarter of 2025, a substantial decline from a net income of $13.162 million in the same period last year. This was largely driven by the absence of collaboration revenue, which was $52.404 million in Q1 2024, following the termination of the Roche Agreement. Operating expenses also decreased, primarily due to strategic re-prioritization and workforce reductions.

Repare Therapeutics announced a restructuring to focus on Phase 1 clinical programs RP-1664 and RP-3467, reducing its workforce by approximately 75%. The company's cash runway extends into late 2027 with $152.8 million in cash and cash equivalents. Initial clinical readouts from the POLAR trial are expected in Q3 2025, and from the LIONS trial in Q4 2025.

Repare Therapeutics reported a net loss of $34.4 million, or $0.81 per share, for the third quarter ended September 30, 2024. The company's cash, cash equivalents, and marketable securities totaled $179.4 million as of September 30, 2024, expected to fund operations into the second half of 2026. Advances were made across the pipeline, including dosing the first patient in the POLAR clinical trial and presenting clinical benefits of camonsertib in combination with radiotherapy.

Repare Therapeutics reported a net loss of $34.8 million, or $0.82 per share, for the second quarter ended June 30, 2024. The company's cash, cash equivalents, and marketable securities totaled $208.1 million as of June 30, 2024. Revenue from collaboration agreements was $1.1 million for the quarter.

Repare Therapeutics reported a net income of $13.2 million for the first quarter of 2024, a significant turnaround from the net loss of $34.9 million in the same period last year. The company's cash and cash equivalents stand at $237.0 million, expected to fund operations into mid-2026. Clinical trials for lunresertib and camonsertib are progressing, with key data readouts anticipated in the near term.

Repare Therapeutics reported a decrease in revenue from collaboration agreements for the three-month period ended December 31, 2023, due to lower deferred revenue recognized from the Roche and BMS collaborations. The company's cash, cash equivalents, and marketable securities totaled $223.6 million as of December 31, 2023.

Repare Therapeutics reported financial results for the third quarter ended September 30, 2023. The company highlighted the advancement of its pipeline, particularly the Phase 1 MYTHIC trial evaluating lunresertib. Initial data from the trial showed early efficacy signals across multiple tumor types, most notably in gynecological tumors, along with a favorable safety and tolerability profile.

Repare Therapeutics reported progress in advancing clinical programs and presenting novel findings from clinical trials during the second quarter of 2023. The company is advancing camonsertib and lunresertib clinical programs and designated a new Polθ inhibitor RP-3467 for IND-enabling studies. Revenue from collaboration agreements increased, and cash reserves are expected to fund operations into 2026.

Repare Therapeutics reported financial results for the first quarter ended March 31, 2023. The company continues to execute clinically and across pipeline programs, including presenting initial clinical data of camonsertib in combination with various PARP inhibitors from the ongoing TRESR and ATTACC trials. They are on track to present initial Phase 1 monotherapy data for RP-6306 in June.

Repare Therapeutics reported fourth-quarter financial results, featuring revenue from collaboration agreements of $18.2 million and a net loss of $31.7 million. The company highlighted progress in its pipeline, including the collaboration with Roche on camonsertib and the Fast Track designation for RP-6306.

Repare Therapeutics reported net income of $75.5 million, or $1.71 diluted earnings per share, and held $370.4 million in cash and cash equivalents and marketable securities as of September 30, 2022. The company believes this will be sufficient to fund planned operations into 2026.

Repare Therapeutics reported revenue of $0.7 million and a net loss of $38.1 million for the second quarter of 2022. They also entered into a worldwide license and collaboration agreement with Roche for camonsertib, receiving a $125 million upfront payment in July 2022.

Repare Therapeutics reported a net loss of $34.8 million, or $0.83 per share, for the first quarter ended March 31, 2022. The company's cash and cash equivalents and marketable securities totaled $311.7 million as of March 31, 2022. Significant progress was made in the RP-3500 program, highlighted by a comprehensive new dataset from the TRESR trial presented at the AACR conference.

Repare Therapeutics reported a net loss of $28.3 million for Q4 2021, with cash and cash equivalents and marketable securities totaling $341.9 million as of December 31, 2021. The company believes its current financial resources will fund operations through 2023. Key progress was made in the RP-3500 and RP-6306 programs.

Repare Therapeutics reported initial data from the Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference, demonstrating a favorable safety profile and promising early activity for RP-3500. The company raised gross proceeds of $101.2 million in an upsized follow-on public offering and appointed Thomas Civik as the new Chairman of the Board. Net loss for the quarter was $30.9 million, or $0.83 per share.

Repare Therapeutics announced the dosing of the first patient in its Phase 1b/2 ATTACC trial of RP-3500 and PARP inhibitor combinations, as well as the dosing of the first patient in the RP-6306 Phase 1 clinical trial. The company's cash and cash equivalents, restricted cash, and marketable securities totaled $301.0 million as of June 30, 2021.

Repare Therapeutics reported a net loss of $21.4 million for the first quarter of 2021. The company highlighted the progress of its RP-3500 and RP-6306 programs and announced the enrollment of the first patient in the RP-6306 Phase 1 clinical trial.

Repare Therapeutics reported a net loss of $15.261 million, or $0.41 per share, for the quarter ended December 31, 2020. The company's cash and cash equivalents, restricted cash, and marketable securities totaled $333.9 million as of December 31, 2020.

Repare Therapeutics reported financial results for Q3 2020. They have advanced their RP-3500 program and expect to initiate a Phase 1 clinical trial for RP-6306 in Q3 2021, ahead of their previously conveyed timeline.

Repare Therapeutics reported a net loss of $11.8 million, or $2.45 per share, for the second quarter of 2020. The company completed an IPO in June, resulting in net proceeds of $232 million, and entered into a collaboration with Bristol Myers Squibb, receiving an upfront payment of $65 million.